Cowen Buys In Vitro Treatment Royalties

AEterna Zentaris Inc. (Nasdaq: AEZS) has agreed to sell Cowen Healthcare Royalty Partners its rights to royalties on future sales of Cetrotide, covered by AEterna's license agreement with Merck Serono. The agreement with Cowen is valued at $52.5 million, plus another $2.5 million in possible earnouts. Cetrotide is a treatment for in virto fertilization.

DealsNorth AmericaUSBriefs